Ocular Therapeutix (OCUL) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts OCUL Hot Sheet
Join SI Premium – FREE
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45).
- PDUFA Target Action Date of July 19, 2017 for the DEXTENZA™ NDA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy shares fall despite beating Q3 estimates
- Alpine Income Property Trust, Inc. (PINE) Tops Q3 EPS by 1c
- Enova International (ENVA) Tops Q3 EPS by 6c, Beats on Revenue
Create E-mail Alert Related Categories
Corporate News, Earnings, FDA, GuidanceRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
